{"brief_title": "A Study of Azithromycin in HIV-Infected Patients", "brief_summary": "To assess the dose proportionality of azithromycin concentrations and toleration when delivered in tablet formulation to HIV-infected patients. The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.", "detailed_description": "The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population. Patients are randomized to receive azithromycin at 1 of 2 doses in a two-treatment, two-period, cross-over study. Dosing visits are separated by at least 14-day wash-out periods.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Azithromycin", "criteria": "Inclusion Criteria Patients must have: - HIV seropositivity. - CD4 count <= 500 cells/mm3. - NO active AIDS opportunistic infection. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Other active intercurrent illness. - Any condition possibly affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies. - Signs or symptoms of severe illness that would preclude study participation. - Known allergies to macrolide antibiotics. Patients with the following prior condition are excluded: Clinically important change in baseline status within 4 weeks prior to study entry. Prior Medication: Excluded: - Investigational drugs including treatment IND drugs within 4 weeks prior to study entry. Known drug or alcohol dependence.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00002344.xml"}